Eltrom
Eltrom Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Eltrom is a brand name. Its generic name is Eltrombopag.
Eltrom
Eltrom is a medication that is used to treat low platelet counts (thrombocytopenia) in patients with chronic immune (idiopathic) thrombocytopenic purpura. It is also used to increase platelet count in patients with hepatitis C virus (HCV) who are undergoing interferon-based treatment.
Uses For
Eltrom is used to reduce the risk of bleeding episodes caused by low platelet count (thrombocytopenia) in people with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to increase platelet count in patients with hepatitis C (HCV) receiving interferon-based therapy.
Mechanism of Action
Eltrom is an orally-administered thrombopoietin (TPO) receptor agonist. It binds to TPO receptors on the surface of megakaryocytes (specialized cells of the bone marrow which give rise to platelets) and stimulates the production of platelets. This increases the number of platelets in circulation.
How Long Does it Take to Work?
Eltrom usually starts to work within 24-72 hours after administration. Its effects last for about 2 weeks, after which platelet count may start to decline again.
Absorption
Eltrom is absorbed rapidly after oral administration and reaches peak concentrations in 1-3 hours.
Route of Elimination
Eltrom is eliminated primarily by metabolism in the liver and to a lesser extent, by renal and fecal excretion.
Dosage
The recommended dose for adults with chronic immune thrombocytopenia purpura (ITP) is 45 mg orally, once daily. The dose should not exceed 90 mg per day. For patients with hepatitis C receiving interferon-based therapy, the recommended dose is 75 mg orally, once daily. The dose should not exceed 150 mg per day.
Administration
Eltrom should be taken with food, as this increases its absorption. It should not be taken with grapefruit or grapefruit juice, as this may increase the amount of eltrombopag in the blood.
Side Effect
Common side effects of eltrombopag may include: headache, runny nose, stomach pain, nausea, vomiting, diarrhea, joint pain, and difficulty sleeping. Rare but serious side effects may include liver failure, decreased blood cell counts, depression, and allergic reactions.
Toxicity
Eltrom is generally well tolerated and its side effects are usually transient and mild in nature. Serious liver toxicity has been reported in some patients, and therefore it is important to monitor liver function tests while taking the drug. Rare but serious hypersensitivity reactions, including anaphylaxis, have also been reported.
Precaution
Eltrom should not be taken by pregnant women. It may also interact with certain other medications, including anticoagulants, antiplatelet drugs, and certain chemotherapy agents, so it should not be taken with these medications. The dose should also be adjusted in patients with impaired liver or kidney function.
Interaction
Eltrom may interact with certain medications, such as anticoagulants, antiplatelet drugs, and chemotherapy agents. It should not be taken with these medications. The dose should also be adjusted in patients with impaired liver or kidney function.
Disease Interaction
Eltrom may interact with certain diseases such as cancer, liver disorders, and immune disorders. Its use should be avoided in patients with these disorders.
Drug Interaction
Eltrom may interact with certain drugs, including anticoagulants, antiplatelet drugs, and certain chemotherapy agents. Its use should be avoided in patients taking these medications.
Food Interactions
Eltrom should be taken with food, as this increases its absorption. It should not be taken with grapefruit or grapefruit juice, as this may increase the amount of eltrombopag in the blood.
Pregnancy Use
Eltrom should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. It is not known if eltrombopag is excreted in breast milk and its use is not recommended in nursing mothers.
Lactation Use
It is not known if eltrombopag is excreted in breast milk and its use is not recommended in nursing mothers.
Acute Overdose
An acute overdose of eltrombopag is unlikely to cause serious toxicity. However, if an overdose occurs, the patient should be monitored for signs and symptoms of toxicity and treated as necessary.
Contraindication
Eltrom is contraindicated in patients with a history of hypersensitivity reaction to eltrombopag or any of its ingredients. It is also contraindicated in patients with severe hypersensitivity reactions to thrombopoietin receptor agonists.
Use Direction
Eltrom should be taken as directed by doctor. The recommended dose for adults with chronic immune thrombocytopenia purpura (ITP) is 45 mg orally, once daily. For patients with hepatitis C receiving interferon-based therapy, the recommended dose is 75 mg orally, once daily.
Storage Condition
Eltrom should be stored at temperatures below 25°C (77°F). Keep the tablets in the original container with the original packaging intact.
Volume of Distribution
The volume of distribution of eltrombopag is reported to be approximately 40 L.
Half Life
The reported elimination half-life of eltrombopag is 6-8 hours.
Clearance
Eltrom is reported to have a clearance of approximately 7 L/hour.
Here you find in details version of Eltrom